Evidence map›Paper›PMID 35203518›Full record

ReviewBiomedicines2022

Cell Technologies in the Stress Urinary Incontinence Correction.

Igor Maiborodin, Gennadiy Yarin, Sergey Marchukov, Aleksandra Pichigina, Galina Lapii, Sergey Krasil'nikov, Svetlana Senchukova, Maxim Ryaguzov, Inna Vilgelmi, Maksim Bakarev and 1 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Igor MaiborodinInstitute of Molecular Pathology and Pathomorphology, Federal State Budget Scientific Institution "Federal Research Center of Fundamental and Translational Medicine" of the Ministry of Science and Higher Education of the Russian Federation, Timakova st., 2, 630117 Novosibirsk, Russia.
Gennadiy YarinThe Center of New Medical Technologies, Institute of Chemical Biology and Fundamental Medicine, The Russian Academy of Sciences, Siberian Branch, akademika Lavrenteva str., 8, 630090 Novosibirsk, Russia.
Sergey MarchukovInstitute of Molecular Pathology and Pathomorphology, Federal State Budget Scientific Institution "Federal Research Center of Fundamental and Translational Medicine" of the Ministry of Science and Higher Education of the Russian Federation, Timakova st., 2, 630117 Novosibirsk, Russia.
Aleksandra PichiginaInstitute of Molecular Pathology and Pathomorphology, Federal State Budget Scientific Institution "Federal Research Center of Fundamental and Translational Medicine" of the Ministry of Science and Higher Education of the Russian Federation, Timakova st., 2, 630117 Novosibirsk, Russia.
Galina LapiiInstitute of Molecular Pathology and Pathomorphology, Federal State Budget Scientific Institution "Federal Research Center of Fundamental and Translational Medicine" of the Ministry of Science and Higher Education of the Russian Federation, Timakova st., 2, 630117 Novosibirsk, Russia.
Sergey Krasil'nikovInstitute of Molecular Pathology and Pathomorphology, Federal State Budget Scientific Institution "Federal Research Center of Fundamental and Translational Medicine" of the Ministry of Science and Higher Education of the Russian Federation, Timakova st., 2, 630117 Novosibirsk, Russia.
Svetlana SenchukovaInstitute of Molecular Pathology and Pathomorphology, Federal State Budget Scientific Institution "Federal Research Center of Fundamental and Translational Medicine" of the Ministry of Science and Higher Education of the Russian Federation, Timakova st., 2, 630117 Novosibirsk, Russia.
Maxim RyaguzovThe Center of New Medical Technologies, Institute of Chemical Biology and Fundamental Medicine, The Russian Academy of Sciences, Siberian Branch, akademika Lavrenteva str., 8, 630090 Novosibirsk, Russia.
Inna VilgelmiThe Center of New Medical Technologies, Institute of Chemical Biology and Fundamental Medicine, The Russian Academy of Sciences, Siberian Branch, akademika Lavrenteva str., 8, 630090 Novosibirsk, Russia.
Maksim BakarevInstitute of Molecular Pathology and Pathomorphology, Federal State Budget Scientific Institution "Federal Research Center of Fundamental and Translational Medicine" of the Ministry of Science and Higher Education of the Russian Federation, Timakova st., 2, 630117 Novosibirsk, Russia.
Vitalina MaiborodinaInstitute of Molecular Pathology and Pathomorphology, Federal State Budget Scientific Institution "Federal Research Center of Fundamental and Translational Medicine" of the Ministry of Science and Higher Education of the Russian Federation, Timakova st., 2, 630117 Novosibirsk, Russia.
Institute of Molecular Pathology and Pathomorphology · RUFederal Research Center of Fundamental and Translational Medicine · RUInstitute of Chemical Biology and Fundamental Medicine · RUSiberian Branch of the Russian Academy of Sciences · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The scientific literature of recent years contains a lot of data about using multipotent stromal cells (MSCs) for urinary incontinence correction. Despite this, the ideal treatment method for urinary incontinence has not yet been created. The cell therapy results in patients and experimental animals with incontinence have shown promising results, but the procedures require further optimization, and more research is needed to focus on the clinical phase. The MSC use appears to be a feasible, safe, and effective method of treatment for patients with urinary incontinence. However, the best mode for application of cell technology is still under study. Most clinical investigations have been performed on only a few patients and during rather short follow-up periods, which, together with an incomplete knowledge of the mechanisms of MSC action, does not make it possible for their widespread implementation. The technical details regarding the MSC application remain to be identified in more rigorous preclinical and clinical trials.

Indexed as

cell therapymultipotent stromal cellsurinary incontinence

Identifiers

PMID35203518
PMCPMC8869383
OpenAlexW4210299161

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.